Oculis Announces Appointment of Daniel S. Char as Chief Legal Officer
Oculis Holding AG (Nasdaq: OCS), a global biopharmaceutical company focused on eye care, has appointed Daniel S. Char as Chief Legal Officer. Mr. Char brings over 35 years of global legal leadership experience in biotech and medical device companies. He will lead Oculis' legal, compliance, and corporate governance functions.
This appointment aligns with Oculis' strategic plan to advance its innovative pipeline, particularly OCS-01, the first topical eye drop in retina. Mr. Char's extensive expertise includes corporate governance, compliance, drug development and commercialization, financing, licensing, and M&A transactions.
Prior to joining Oculis, Mr. Char served as Chief Legal Officer at ImmunoGen and General Counsel at Evelo Biosciences. He has also held senior legal positions at Smith & Nephew, Targanta Therapeutics, and Biogen. Mr. Char holds a Juris Doctor from Harvard Law School and a Bachelor of Arts in Economics from Tufts University.
Oculis Holding AG (Nasdaq: OCS), un'azienda biofarmaceutica globale focalizzata sulla cura degli occhi, ha nominato Daniel S. Char come Chief Legal Officer. Il sig. Char porta con sé oltre 35 anni di esperienza nella leadership legale globale nelle aziende biotech e dispositivi medici. Condurrà le funzioni legali, di conformità e governance aziendale di Oculis.
Questa nomina si allinea al piano strategico di Oculis per far avanzare il suo innovativo pipeline, in particolare OCS-01, la prima goccia oculare topica per la retina. L'ampia competenza del sig. Char include governance aziendale, conformità, sviluppo e commercializzazione di farmaci, finanziamenti, licenze e operazioni di M&A.
Prima di unirsi a Oculis, il sig. Char ha ricoperto il ruolo di Chief Legal Officer presso ImmunoGen e di General Counsel presso Evelo Biosciences. Ha anche ricoperto posizioni legali senior presso Smith & Nephew, Targanta Therapeutics e Biogen. Il sig. Char ha conseguito un Juris Doctor presso la Harvard Law School e un Bachelor of Arts in Economia presso la Tufts University.
Oculis Holding AG (Nasdaq: OCS), una empresa biofarmacéutica global enfocada en el cuidado ocular, ha designado a Daniel S. Char como Chief Legal Officer. El Sr. Char aporta más de 35 años de experiencia en liderazgo legal global en empresas de biotecnología y dispositivos médicos. Él dirigirá las funciones legales, de cumplimiento y de gobernanza corporativa de Oculis.
Esta designación se alinea con el plan estratégico de Oculis para avanzar en su innovador pipeline, particularmente OCS-01, la primera gota ocular tópica para la retina. La amplia experiencia del Sr. Char incluye gobernanza corporativa, cumplimiento, desarrollo y comercialización de fármacos, financiamiento, licencias y transacciones de M&A.
Antes de unirse a Oculis, el Sr. Char se desempeñó como Chief Legal Officer en ImmunoGen y como General Counsel en Evelo Biosciences. También ha ocupado puestos legales senior en Smith & Nephew, Targanta Therapeutics y Biogen. El Sr. Char posee un Juris Doctor de Harvard Law School y un Bachelor of Arts en Economía de Tufts University.
Oculis Holding AG (Nasdaq: OCS)는 안구 치료에 중점을 둔 글로벌 생물제약 회사로, Daniel S. Char를 최고 법무 책임자로 임명했습니다. Char 씨는 생명공학 및 의료기기 기업에서 35년 이상의 글로벌 법률 리더십 경험을 가지고 있습니다. 그는 Oculis의 법률, 컴플라이언스 및 기업 거버넌스 기능을 이끌게 됩니다.
이번 임명은 Oculis의 혁신적인 파이프라인, 특히 망막을 위한 첫 번째 점안액인 OCS-01을 발전시키려는 전략적 계획과 일치합니다. Char 씨의 방대한 전문성에는 기업 거버넌스, 컴플라이언스, 약물 개발 및 상용화, 자금 조달, 라이선스 및 M&A 거래가 포함됩니다.
Oculis에 합류하기 전, Char 씨는 ImmunoGen의 최고 법무 책임자 및 Evelo Biosciences의 법률 고문으로 근무했습니다. 그는 또한 Smith & Nephew, Targanta Therapeutics 및 Biogen에서 고위 법률 직책을 역임했습니다. Char 씨는 Harvard Law School에서 법학 박사(Juris Doctor)를, Tufts University에서 경제학 학사(Bachelor of Arts)를 받았습니다.
Oculis Holding AG (Nasdaq: OCS), une entreprise biopharmaceutique mondiale axée sur les soins oculaires, a nommé Daniel S. Char au poste de Chief Legal Officer. M. Char apporte plus de 35 ans d'expérience en leadership juridique mondial dans des entreprises de biotechnologie et de dispositifs médicaux. Il dirigera les fonctions juridiques, de conformité et de gouvernance d'entreprise d'Oculis.
Cette nomination s'inscrit dans le plan stratégique d'Oculis visant à faire progresser son pipeline innovant, en particulier OCS-01, la première goutte oculaire topique pour la rétine. L'expertise approfondie de M. Char inclut la gouvernance d'entreprise, la conformité, le développement et la commercialisation de médicaments, le financement, la licence et les transactions de fusions et acquisitions.
Avant de rejoindre Oculis, M. Char a été Chief Legal Officer chez ImmunoGen et General Counsel chez Evelo Biosciences. Il a également occupé des postes juridiques senior chez Smith & Nephew, Targanta Therapeutics et Biogen. M. Char est titulaire d'un Juris Doctor de la Harvard Law School et d'un Bachelor of Arts en économie de l'Université de Tufts.
Oculis Holding AG (Nasdaq: OCS), ein globales biopharmazeutisches Unternehmen, das sich auf die Augengesundheit spezialisiert hat, hat Daniel S. Char zum Chief Legal Officer ernannt. Herr Char bringt über 35 Jahre globale rechtliche Führungserfahrung in Biotech- und Medizintechnikunternehmen mit. Er wird die rechtlichen, compliance- und corporate governance-Funktionen von Oculis leiten.
Diese Ernennung steht im Einklang mit dem strategischen Plan von Oculis, um seine innovative Pipeline voranzutreiben, insbesondere OCS-01, die erste topische Augentropfenlösung für die Netzhaut. Herr Chars umfangreiche Expertise umfasst Unternehmensführung, Compliance, Arzneimittelentwicklung und -vermarktung, Finanzierung, Lizenzierung und M&A-Transaktionen.
Vor seinem Eintritt bei Oculis war Herr Char Chief Legal Officer bei ImmunoGen und General Counsel bei Evelo Biosciences. Er hatte auch leitende Rechtspositionen bei Smith & Nephew, Targanta Therapeutics und Biogen inne. Herrn Char hat einen Juris Doctor von der Harvard Law School und einen Bachelor of Arts in Wirtschaftswissenschaften von der Tufts University.
- Appointment of experienced Chief Legal Officer with 35+ years in biotech and medical device companies
- Strengthening of leadership team to support pipeline advancement and commercial preparation
- Progress in executing strategic plan, particularly for OCS-01 as first topical eye drop in retina
- None.
ZUG, Switzerland, Oct. 02, 2024 (GLOBE NEWSWIRE) --
- Mr. Char brings extensive experience in leading legal, compliance and corporate governance functions in successful biotech and medical device companies
- The appointment further expands Oculis’ leadership team as the company advances its late-stage pipeline and prepares for commercial phase
Oculis Holding AG (Nasdaq: OCS) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced the appointment of Daniel S. Char to the role of Chief Legal Officer, leading Oculis’ legal, compliance and corporate governance functions. Mr. Char brings over 35 years of success in global legal leadership experience at both large and smaller biotech companies.
Riad Sherif, MD, Chief Executive Officer of Oculis, said: “We are delighted to welcome Daniel to Oculis. This appointment exemplifies our continued execution of Oculis’ strategic plan to advance our innovative pipeline and bring differentiated products to patients starting with OCS-01 as the first topical eye drop in retina.
Daniel S. Char, Chief Legal Officer of Oculis commented: “I am thrilled to have the opportunity to join Oculis, a company with both an exceptional track record of strategic execution and multiple anticipated near-term milestones. I look forward to working alongside a talented team and supporting the company at this pivotal stage as it continues its journey to become a world leader in ophthalmology.”
Mr. Char brings to Oculis extensive legal expertise in corporate governance, compliance, drug development and commercialization, financing, licensing, and merger and acquisition transactions. Mr. Char joins Oculis from ImmunoGen where he served as Chief Legal Officer and Corporate Secretary. From 2018 to 2022, Mr. Char was the General Counsel and Corporate Secretary of Evelo Biosciences. Before that, Mr. Char held legal positions of increasing seniority with several biotech and medical device companies, including Smith & Nephew, Targanta Therapeutics, and Biogen. Mr. Char began his career as a corporate associate with Goodwin Procter. Mr. Char holds a Juris Doctor degree from Harvard Law School and a Bachelor of Arts in Economics from Tufts University.
-ENDS-
About Oculis
Oculis is a global biopharmaceutical company (Nasdaq: OCS; XICE: OCS) purposefully driven to save sight and improve eye care. Oculis’ highly differentiated pipeline comprises multiple innovative product candidates in development. It includes OCS-01, a topical eye drop candidate for diabetic macular edema (DME) and for the treatment of inflammation and pain following cataract surgery; OCS-02 (licaminlimab), a topical biologic anti-TNFα eye drop candidate for dry eye disease (DED) and for non-infectious anterior uveitis; and OCS-05, a neuroprotective candidate for acute optic neuritis (AON). Headquartered in Switzerland and with operations in the U.S. and Iceland, Oculis’ goal is to improve the health and quality of life of patients worldwide. The company is led by an experienced management team with a successful track record and is supported by leading international healthcare investors.
For more information, please visit: www.oculis.com
Oculis Contact
Ms. Sylvia Cheung, CFO
sylvia.cheung@oculis.com
Investor & Media Relations
LifeSci Advisors
Corey Davis, Ph.D.
cdavis@lifesciadvisors.com
1-212-915-2577
Cautionary Statement Regarding Forward Looking Statements
This press release contains forward-looking statements. For example, statements regarding the progress and results of Oculis’ clinical studies; Oculis’ research and development programs, regulatory and business strategy and future development plans; and the timing or likelihood of regulatory filings and approvals are forward-looking. All forward-looking statements are based on estimates and assumptions that, while considered reasonable by Oculis and its management, are inherently uncertain and are inherently subject to risks, variability, and contingencies, many of which are beyond Oculis’ control. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by an investor as, a guarantee, assurance, prediction or definitive statement of a fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. All forward-looking statements are subject to risks, uncertainties and other factors that may cause actual results to differ materially from those that we expected and/or those expressed or implied by such forward-looking statements. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of Oculis, including those set forth in the Risk Factors section of Oculis’ annual report on Form 20-F and other documents filed with the U.S. Securities and Exchange Commission (the “SEC”). Copies of these documents are available on the SEC’s website, www.sec.gov. The forward-looking statements in this press release speak only as of the date of this press release. Oculis undertakes no obligation to update any forward-looking statements, whether as a result of new information, future developments or otherwise, except as required by law.
FAQ
Who is the new Chief Legal Officer of Oculis (OCS)?
What is Oculis (OCS) focusing on in its pipeline?
What is Daniel S. Char's background before joining Oculis (OCS)?
What are the key responsibilities of Daniel S. Char at Oculis (OCS)?
